For example, the Inflation Reduction Act’s (IRA’s) drug price negotiation provisions, inflation rebates, and Medicare Part D discount requirements, along with recently proposed most-favored-nation pricing models issued by the Centers for Medicare and Medicaid Services, could significantly impact our ability to obtain adequate pricing for our product candidates.
